Welcome to our dedicated page for Immix Biopharma news (Ticker: IMMX), a resource for investors and traders seeking the latest updates and insights on Immix Biopharma stock.
Immix Biopharma, Inc. (Nasdaq: IMMX) generates a steady flow of news as a clinical-stage biopharmaceutical company advancing cell therapies for relapsed/refractory AL amyloidosis and other serious diseases. The company describes itself as a global leader in this rare blood disorder, and its news coverage reflects progress in clinical development, regulatory interactions, capital formation and corporate governance.
Many Immix Biopharma news items focus on its lead BCMA-targeted CAR-T cell therapy, NXC-201, and the ongoing NEXICART-2 clinical trial in relapsed/refractory AL amyloidosis. Press releases highlight interim and Phase 2 results, including complete response rates, organ responses and safety observations, as well as the selection of NXC-201 data for oral presentations at major conferences such as ASH and ASCO. The company also reports on regulatory designations for NXC-201, including RMAT and Orphan Drug Designation from U.S. and European authorities.
Investors following IMMX news will also see announcements about equity financings, including registered underwritten offerings and private placements of common stock and warrants, together with stated uses of proceeds for NXC-201 development and general corporate purposes. Additional coverage includes board and management changes, such as the appointment of experienced biotechnology leaders to the board of directors and the addition of a Chief Commercial Officer to prepare for potential commercialization of NXC-201.
This news page aggregates company press releases and related updates so readers can track Immix Biopharma’s clinical milestones, financing activities, conference presentations and strategic appointments over time.
Immix Biopharma (Nasdaq: IMMX) has received IRB approval for enrolling pediatric patients in its IMX-110 clinical trial, crucial for FDA's Priority Review Voucher (PRV) approval. The PRV enables expedited review for new drug applications. Historically, these vouchers sell for $67 to $350 million. The company is focusing on treating pediatric rhabdomyosarcoma, a severe childhood cancer, and soft tissue sarcoma in adults. IMX-110 is part of ImmixBio's innovative Tissue-Specific Therapeutics platform, enhancing treatment efficacy by targeting tumor sites more effectively.
Immix Biopharma, Inc. (Nasdaq: IMMX) announced that CEO Ilya Rachman and CFO Gabriel Morris will present a company overview at the ThinkEquity Conference on October 26, 2022, at 2:00 PM ET. The presentation will highlight milestones achieved to kick off two clinical trials for IMX-110, which is currently in Phase 1b/2a trials with orphan drug designation for soft tissue sarcoma and Rare Pediatric Disease Designation for rhabdomyosarcoma. Expectations are for clinical trial data to be released in Q1 2023.
Immix Biopharma (Nasdaq: IMMX) has expanded its clinical trial consortium by adding four additional oncology sites to enhance the testing of its drug IMX-110 for soft tissue sarcoma. The lead site in California has historically enrolled 2-3 patients monthly. As part of the trial, patients will receive CT scans every eight weeks to monitor tumor response, with data release commencing in Q1 2023. The FDA has granted orphan drug designation and rare pediatric disease designation for IMX-110, enabling potential fast track and priority review upon marketing approval.
Immix Biopharma (Nasdaq: IMMX) has successfully completed Good Manufacturing Practice (GMP) manufacturing of IMX-110, a drug candidate for clinical trials. This scaled-up process will support two upcoming clinical trials: one for monotherapy in soft tissue sarcoma and another combining IMX-110 with BeiGene's anti-PD-1 tislelizumab for advanced solid tumors. The FDA has granted orphan drug and rare pediatric disease designations for IMX-110, enabling it to benefit from expedited review processes. The company aims to initiate these trials in 2022.
Immix Biopharma (Nasdaq: IMMX) announced promising interim results for IMX-110 from a Soft Tissue Sarcoma (STS) mice study. After one treatment cycle, IMX-110 demonstrated a 75% survival rate compared to 0% for Trabectedin, an FDA-approved drug. This positions IMX-110 favorably in a potential $3 billion STS market projected to reach $6.5 billion by 2030. CEO Ilya Rachman expressed optimism ahead of two clinical trials for IMX-110 set to begin in 2022.
Immix Biopharma (Nasdaq: IMMX) has authorized a $1 million stock buyback program to enhance shareholder value. The company, with approximately $18 million in cash and equivalents as of December 31, 2021, and 13.9 million shares outstanding, aims to execute purchases based on market conditions and regulatory considerations. CEO Ilya Rachman expressed confidence in reaching critical milestones with their lead asset, IMX-110, while emphasizing alignment with shareholder interests.
Immix Biopharma, Inc. (Nasdaq: IMMX) announced its Milestone Day Event on April 5, 2022, showcasing its drug development progress and the company’s financial position after raising $24.2 million in its IPO. Management outlined plans to begin two clinical trials in 2022, specifically for its lead asset, IMX-110, which targets oncology and immuno-dysregulated diseases. The event highlighted the company’s unique Tissue-Specific Therapeutics (TSTx) approach and its orphan drug designation for soft tissue sarcoma. For more information, visit immixbio.com.
Immix Biopharma, Inc. (Nasdaq: IMMX) announced plans for the IMMX Milestone Day Event on April 5, 2022, where management will discuss the company’s financial position, milestones, and market opportunities amid current volatility. The company raised $24.2 million from its December 2021 IPO and aims to initiate two clinical trials in 2022. CEO Ilya Rachman expressed confidence in achieving planned milestones with the capital raised, emphasizing the company's strategy to leverage market conditions for growth.
Immix Biopharma (Nasdaq: IMMX) has initiated Good Manufacturing Practice (GMP) manufacturing for IMX-120, a biologic targeting inflammatory bowel disease (IBD). The company plans to file an Investigational New Drug (IND) application for IMX-120 in 2023, marking an important milestone for future clinical trials. The IBD market is projected to grow from $18.4 billion in 2019 to $21.4 billion by 2024, underscoring the potential market opportunity for IMX-120. This development highlights ImmixBio's commitment to advancing treatment options in the biopharmaceutical sector.
Immix Biopharma has hosted an Investors Day event on February 1, 2022, where management responded to top-voted questions from verified shareholders. The session highlighted the company’s commitment to transparency and ongoing communication with investors. ImmixBio is focused on its lead asset, IMX-110, currently in Phase 1b/2a clinical trials for soft tissue sarcoma and rhabdomyosarcoma, supported by orphan drug and rare pediatric designations by the FDA.